The role of biomarkers in stage III non-small cell lung cancer

被引：0

作者：

Rosell, Rafael ^{[1
,2
,3
,7
]}

Gonzalez-Cao, Maria ^{[1
]}

Ito, Masaoki ^{[4
]}

Santarpia, Mariacarmela ^{[5
]}

Aguilar, Andres ^{[1
]}

Codony-Servat, Jordi ^{[6
]}

机构：

[1] Dexeus Univ Hosp, Translat Canc Res Unit, Inst Oncol Dr Rosell, Barcelona, Spain

[2] Germans Trias I Pujol Hlth Sci Inst & Hosp IGTP, Lab Mol Biol Canc, Badalona, Spain

[3] Catalan Inst Oncol, Med Oncol Dept, Badalona, Spain

[4] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan

[5] Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy

[6] Quiron Dexeus Univ Hosp, Lab Oncol, Pangaea Oncol, Barcelona, Spain

[7] Germans Trias I Pujol Hlth Sci Inst & Hosp IGTP, Lab Mol Biol, Cami Escoles S-N, Badalona 08916, Barcelona, Spain

来源：

EXPERT REVIEW OF RESPIRATORY MEDICINE | 2023年 / 17卷 / 06期

关键词：

Stage III NSCLC; ferroptosis; Durvalumab; DHODH; p53; KEAP1; NRF2; chemoradiation; FERROPTOSIS; MUTATIONS; IMMUNOTHERAPY; ACTIVATION; PATHWAY; NSCLC; P53; CHEMOTHERAPY; DURVALUMAB; RESISTANCE;

D O I：

10.1080/17476348.2023.2223985

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

IntroductionStage III non-small cell lung cancer (NSCLC) is a composite of the regional spread of lung cancer with different levels of potential lymph node involvement and tumor size that often deem the stage at time of diagnosis to be unresectable and suitable for chemoradiation plus consolidation immunotherapy with durvalumab for 12 months. Chemoradiation plus durvalumab consolidation yielded a landmark 49.2% 5-year overall survival in unresectable NSCLC.Areas coveredSub-optimal results lead us to focus on the mechanisms of resistance responsible for intractability in a significant proportion of cases that fail with chemoradiation and immunotherapy. In stage III NSCLC it is opportune to explore the accumulated evidence on ferroptosis resistance that can lead to cancer progression and metastasis. Strong data shows that three anti-ferroptosis pathways are principally involved in resistance to chemotherapy, radiation, and immunotherapy.Expert opinionBecause a large part of stage III NSCLCs is resistant to chemoradiation and durvalumab consolidation, a ferroptosis-based therapeutic approach, combined with standard-of-care therapy, can lead to improved clinical outcomes in patients diagnosed with stage III and possibly stage IV NSCLCs.

引用

页码：469 / 480

页数：12

共 77 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[2] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy [J].

Aredo, Jacqueline V. ;

Mambetsariev, Isa ;

Hellyer, Jessica A. ;

Amini, Arya ;

Neal, Joel W. ;

Padda, Sukhmani K. ;

McCoach, Caroline E. ;

Riess, Jonathan W. ;

Cabebe, Elwyn C. ;

Naidoo, Jarushka ;

Abuali, Tariq ;

Salgia, Ravi ;

Loo Jr, Billy W. ;

Diehn, Maximilian ;

Han, Summer S. ;

Wakelee, Heather A. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) :1030-1041

[3] The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis [J].

Bersuker, Kirill ;

Hendricks, Joseph M. ;

Li, Zhipeng ;

Magtanong, Leslie ;

Ford, Breanna ;

Tang, Peter H. ;

Roberts, Melissa A. ;

Tong, Bingqi ;

Maimone, Thomas J. ;

Zoncu, Roberto ;

Bassik, Michael C. ;

Nomura, Daniel K. ;

Dixon, Scott J. ;

Olzmann, James A. .

NATURE, 2019, 575 (7784) :688-+

[4]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[5] Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations [J].

Carrot-Zhang, Jian ;

Soca-Chafre, Giovanny ;

Patterson, Nick ;

Thorner, Aaron R. ;

Nag, Anwesha ;

Watson, Jacqueline ;

Genovese, Giulio ;

Rodriguez, July ;

Gelbard, Maya K. ;

Corrales-Rodriguez, Luis ;

Mitsuishi, Yoichiro ;

Ha, Gavin ;

Campbell, Joshua D. ;

Oxnard, Geoffrey R. ;

Arrieta, Oscar ;

Cardona, Andres F. ;

Gusev, Alexander ;

Meyerson, Matthew .

CANCER DISCOVERY, 2021, 11 (03) :591-598

[6] Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer [J].

Cronin, Shane J. F. ;

Rao, Shuan ;

Tejada, Miguel A. ;

Turnes, Bruna Lenfers ;

Licht-Mayer, Simon ;

Omura, Takao ;

Brenneis, Christian ;

Jacobs, Emily ;

Barrett, Lee ;

Latremoliere, Alban ;

Andrews, Nick ;

Channon, Keith M. ;

Latini, Alexandra ;

Arvanites, Anthony C. ;

Davidow, Lance S. ;

Costigan, Michael ;

Rubin, Lee L. ;

Penninger, Josef M. ;

Woolf, Clifford J. .

SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (660)

[7] Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline [J].

Daly, Megan E. ;

Singh, Navneet ;

Ismaila, Nofisat ;

Antonoff, Mara B. ;

Arenberg, Douglas A. ;

Bradley, Jeffrey ;

David, Elizabeth ;

Detterbeck, Frank ;

Fruh, Martin ;

Gubens, Matthew A. ;

Moore, Amy C. ;

Padda, Sukhmani K. ;

Patel, Jyoti D. ;

Phillips, Tanyanika ;

Qin, Angel ;

Robinson, Clifford ;

Simone, Charles B., II .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) :1356-+

[8] Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis [J].

De Nicola, Gina M. ;

Karreth, Florian A. ;

Humpton, Timothy J. ;

Gopinathan, Aarthi ;

Wei, Cong ;

Frese, Kristopher ;

Mangal, Dipti ;

Yu, Kenneth H. ;

Yeo, Charles J. ;

Calhoun, Eric S. ;

Scrimieri, Francesca ;

Winter, Jordan M. ;

Hruban, Ralph H. ;

Iacobuzio-Donahue, Christine ;

Kern, Scott E. ;

Blair, Ian A. ;

Tuveson, David A. .

NATURE, 2011, 475 (7354) :106-U128

[9] Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death [J].

Dixon, Scott J. ;

Lemberg, Kathryn M. ;

Lamprecht, Michael R. ;

Skouta, Rachid ;

Zaitsev, Eleina M. ;

Gleason, Caroline E. ;

Patel, Darpan N. ;

Bauer, Andras J. ;

Cantley, Alexandra M. ;

Yang, Wan Seok ;

Morrison, Barclay, III ;

Stockwell, Brent R. .

CELL, 2012, 149 (05) :1060-1072

[10] FSP1 is a glutathione-independent ferroptosis suppressor [J].

Doll, Sebastian ;

Freitas, Florencio Porto ;

Shah, Ron ;

Aldrovandi, Maceler ;

da Silva, Milene Costa ;

Ingold, Irina ;

Grocin, Andrea Goya ;

da Silva, Thamara Nishida Xavier ;

Panzilius, Elena ;

Scheel, Christina H. ;

Mourao, Andre ;

Buday, Katalin ;

Sato, Mami ;

Wanninger, Jonas ;

Vignane, Thibaut ;

Mohana, Vaishnavi ;

Rehberg, Markus ;

Flatley, Andrew ;

Schepers, Aloys ;

Kurz, Andreas ;

White, Daniel ;

Sauer, Markus ;

Sattler, Michael ;

Tate, Edward William ;

Schmitz, Werner ;

Schulze, Almut ;

O'Donnell, Valerie ;

Proneth, Bettina ;

Popowicz, Grzegorz M. ;

Pratt, Derek A. ;

Angeli, Jose Pedro Friedmann ;

Conrad, Marcus .

NATURE, 2019, 575 (7784) :693-+

← 1 2 3 4 5 6 7 8 →